GTx falls on poor Phase III prostate cancer data
This article was originally published in Scrip
Executive Summary
GTX's toremifene failed to significantly reduce the incidence of prostate cancer in men with premalignant prostate lesions, show top-line results from a GTx-sponsored trial. The company's share price fell by 50% to $2.00 on Nasdaq when the news was announced earlier this week.